BR112012004395B8 - plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo - Google Patents

plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo

Info

Publication number
BR112012004395B8
BR112012004395B8 BR112012004395A BR112012004395A BR112012004395B8 BR 112012004395 B8 BR112012004395 B8 BR 112012004395B8 BR 112012004395 A BR112012004395 A BR 112012004395A BR 112012004395 A BR112012004395 A BR 112012004395A BR 112012004395 B8 BR112012004395 B8 BR 112012004395B8
Authority
BR
Brazil
Prior art keywords
plasmid
sdf
left ventricular
injectable preparation
derived factor
Prior art date
Application number
BR112012004395A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012004395A2 (pt
BR112012004395B1 (pt
Inventor
Pastore Joseph
S Penn Marc
Aras Rahul
R Miller Timothy
Original Assignee
Cleveland Clinic Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Found filed Critical Cleveland Clinic Found
Publication of BR112012004395A2 publication Critical patent/BR112012004395A2/pt
Publication of BR112012004395B1 publication Critical patent/BR112012004395B1/pt
Publication of BR112012004395B8 publication Critical patent/BR112012004395B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112012004395A 2009-08-28 2010-08-30 plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo BR112012004395B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23777509P 2009-08-28 2009-08-28
US61/237,775 2009-08-28
US33421610P 2010-05-13 2010-05-13
US61/334,216 2010-05-13
PCT/US2010/047175 WO2011026041A2 (en) 2009-08-28 2010-08-30 Sdf-1 delivery for treating ischemic tissue

Publications (3)

Publication Number Publication Date
BR112012004395A2 BR112012004395A2 (pt) 2016-11-16
BR112012004395B1 BR112012004395B1 (pt) 2021-01-12
BR112012004395B8 true BR112012004395B8 (pt) 2021-05-25

Family

ID=43628693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004395A BR112012004395B8 (pt) 2009-08-28 2010-08-30 plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo

Country Status (9)

Country Link
US (5) US20120283315A1 (enExample)
EP (1) EP2473196B1 (enExample)
JP (1) JP5856059B2 (enExample)
CN (1) CN102740894B (enExample)
AU (1) AU2010286511B2 (enExample)
BR (1) BR112012004395B8 (enExample)
CA (1) CA2772610C (enExample)
MX (1) MX357779B (enExample)
WO (1) WO2011026041A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US20120283315A1 (en) 2009-08-28 2012-11-08 Penn Marc S Sdf-1 delivery for treating ischemic tissue
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20130295064A1 (en) * 2010-10-14 2013-11-07 University Of Central Florida Research Foundation, Inc. Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium
US20130136729A1 (en) * 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
EP2968608A4 (en) * 2013-03-15 2016-10-26 Cleveland Clinic Foundation RETROGRADE ADMINISTRATION OF SDF-1 FOR THE TREATMENT OF MYOCARDIAL INFARCTION
JP6461085B2 (ja) * 2013-03-15 2019-01-30 ザ クリーブランド クリニック ファウンデーション 虚血性組織を治療するためのｓｄｆ−１送達
CN105263507A (zh) * 2013-03-15 2016-01-20 尤文塔斯医疗公司 使用sdf-1减轻瘢痕形成
US20160278810A1 (en) 2013-05-31 2016-09-29 Mark Edmund Richey Vaginal surgical apparatus
US10166044B1 (en) 2013-05-31 2019-01-01 Freshwater Bay Industries, Llc Apparatus for repositioning the vagina, cervix, uterus and pelvic floor and method to secure same
US20170049856A1 (en) * 2014-04-28 2017-02-23 Juventas Therapeutics, Inc. Sdf-1 delivery for treating advanced ischemic cardiomyopathy
US10420818B2 (en) 2014-05-08 2019-09-24 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
CA2971520C (en) 2014-12-23 2024-04-09 Ilya Pharma Ab Methods for wound healing
MA43404A (fr) 2015-11-11 2018-10-17 Intrexon Corp Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques
WO2018183625A1 (en) * 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2018213125A1 (en) 2017-05-13 2018-11-22 The Johns Hopkins University Stromal derived factor 1 and it's use in the prevention and treatment of erectile dysfunction
WO2019032930A1 (en) 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
EP3781182A4 (en) * 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US20020031803A1 (en) * 1997-06-20 2002-03-14 Cooper Mark J. Expression system for production of therapeutic proteins
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
PL334902A1 (en) * 1997-01-29 2000-03-27 Cornell Res Foundation Inc Repeatable local delivery of adenoviral vector in order to induce angiogenesis
IL132838A (en) 1997-06-13 2004-08-31 Genentech Inc Protein recovery by chromatography followed by filtration upon a charged layer
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
EP1061800A4 (en) 1998-03-09 2004-10-06 Caritas St Elizabeths Boston COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
JP4786793B2 (ja) 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス，インコーポレイティド 腫瘍形成におけるｃｘｃｒ−４遺伝子の役割に基く治療的および診断的応用
US20020107195A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
WO2000006086A2 (en) 1998-07-31 2000-02-10 The Trustees Of Columbia University In The City Of New York Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2000015285A1 (en) * 1998-09-14 2000-03-23 Mirus Corporation A process for delivering nucleic acids to cardiac tissue
DE19844479C1 (de) 1998-09-28 2000-04-13 Siemens Ag Integrierter Speicher mit einem differentiellen Leseverstärker
US7399751B2 (en) 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
EP1013770A1 (en) * 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE19900743A1 (de) * 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
CA2366707A1 (en) 1999-02-26 2000-08-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Bone marrow transplantation for hepatic regeneration and repair
US20050153451A1 (en) * 1999-02-26 2005-07-14 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
EP1041148A1 (en) 1999-04-02 2000-10-04 Mogen International N.V. Pathogen inducible promoter
CA2367173A1 (en) 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
AU4801501A (en) * 2000-05-26 2001-11-29 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
CA2810249A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury
US20020061587A1 (en) * 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US7402567B2 (en) 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
AU2002235168A1 (en) 2000-11-05 2002-05-15 University Of Florida Targeting pluripotent stem cells to tissues
AU2002224851A1 (en) 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
CA2430401A1 (en) 2000-12-01 2002-06-06 Schering Corporation Uses of mammalian genes and related reagents
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
JPWO2003014336A1 (ja) 2001-08-07 2004-11-25 麒麟麦酒株式会社 造血幹細胞の製造法
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
WO2003059375A1 (en) 2002-01-17 2003-07-24 Cardio Incorporated Complex therapy for tissue regeneration
FR2843697B1 (fr) * 2002-08-26 2005-12-09 Sod Conseils Rech Applic L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses
US7396537B1 (en) 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
JP2004099471A (ja) 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
WO2004033396A2 (en) 2002-10-08 2004-04-22 American National Red Cross Method for enriching adherent monocyte populations
US20040258669A1 (en) 2002-11-05 2004-12-23 Dzau Victor J. Mesenchymal stem cells and methods of use thereof
WO2004052177A2 (en) 2002-12-05 2004-06-24 Case Western Reserve University Cell-based therapies for ischemia
JPWO2004074494A1 (ja) * 2003-02-19 2006-06-01 株式会社ディナベック研究所 虚血疾患の治療方法
AU2003902037A0 (en) 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US20050104072A1 (en) 2003-08-14 2005-05-19 Slater David B.Jr. Localized annealing of metal-silicon carbide ohmic contacts and devices so formed
US7396680B2 (en) 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005062881A2 (en) * 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
EP1771196B1 (en) 2004-06-21 2012-03-28 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
EP1803464A4 (en) 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
EP1804813A4 (en) * 2004-09-27 2011-09-07 Vical Inc FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20060105950A1 (en) 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
US20060166361A1 (en) 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US7951632B1 (en) 2005-01-26 2011-05-31 University Of Central Florida Optical device and method of making
GB2424312B (en) 2005-03-14 2010-03-03 Denso Corp Method of forming an ohmic contact in wide band semiconductor
JP2009509339A (ja) 2005-09-16 2009-03-05 クリー インコーポレイテッド 炭化ケイ素パワーデバイスを有する半導体ウェハを処理する方法
JP5386177B2 (ja) 2006-01-10 2014-01-15 クリー インコーポレイテッド 炭化珪素ディンプル基板
US20070173471A1 (en) 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US20120283315A1 (en) 2009-08-28 2012-11-08 Penn Marc S Sdf-1 delivery for treating ischemic tissue
US20130252876A1 (en) 2010-09-15 2013-09-26 The Cleveland Clinic Foundation Compositions and method for promoting musculoskeletal repair
US20120068161A1 (en) 2010-09-16 2012-03-22 Lee Keon-Jae Method for forming graphene using laser beam, graphene semiconductor manufactured by the same, and graphene transistor having graphene semiconductor
JP5569376B2 (ja) 2010-12-07 2014-08-13 住友電気工業株式会社 半導体装置の製造方法

Also Published As

Publication number Publication date
JP2013503202A (ja) 2013-01-31
CA2772610A1 (en) 2011-03-03
US8513213B2 (en) 2013-08-20
WO2011026041A9 (en) 2011-07-21
US9844581B2 (en) 2017-12-19
US8883756B2 (en) 2014-11-11
EP2473196A2 (en) 2012-07-11
EP2473196B1 (en) 2017-05-31
CA2772610C (en) 2018-01-23
US8513007B2 (en) 2013-08-20
CN102740894A (zh) 2012-10-17
CN102740894B (zh) 2015-07-15
US20120283315A1 (en) 2012-11-08
AU2010286511B2 (en) 2016-05-26
US20120289586A1 (en) 2012-11-15
US20130303597A1 (en) 2013-11-14
US20120289585A1 (en) 2012-11-15
MX2012002610A (es) 2012-08-23
AU2010286511A1 (en) 2012-04-12
EP2473196A4 (en) 2015-01-07
BR112012004395A2 (pt) 2016-11-16
JP5856059B2 (ja) 2016-02-09
WO2011026041A2 (en) 2011-03-03
BR112012004395B1 (pt) 2021-01-12
US20140135383A1 (en) 2014-05-15
MX357779B (es) 2018-07-24

Similar Documents

Publication Publication Date Title
BR112012004395B8 (pt) plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo
Capel et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential
Khan Atrial stunning: determinants and cellular mechanisms
Zhang et al. Autophagy mediates the beneficial effect of hypoxic preconditioning on bone marrow mesenchymal stem cells for the therapy of myocardial infarction
Yi et al. Ion therapy: a novel strategy for acute myocardial infarction
CR9933A (es) Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias
CR10169A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para disminuir lipidos y disminuir niveles de glucosa en la sangre"
WO2008096268A3 (en) Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
BRPI0512583A (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções
BRPI0617664B8 (pt) uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
WO2014153160A3 (en) METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING
Huang et al. Antiarrhythmic effects and ionic mechanisms of allicin on myocardial injury of diabetic rats induced by streptozotocin
CY1115619T1 (el) Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων
AR050148A1 (es) Implante y metodo para aumentar y mejorar tejidos
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
Yang et al. Sodium tanshinone IIA sulfonate attenuates the transforming growth factor-β1-induced differentiation of atrial fibroblasts into myofibroblasts in vitro
NO20056000L (no) Vevsbeskyttende cytokiner for beskyttelse, gjenoppbygging og okning av responsivceller, vev og organer med et utvidet terapeutisk vindu
WO2007001339A3 (en) Ambient stored blood plasma expanders
AR073800A1 (es) Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196
JP2017522392A5 (enExample)
CL2009000986A1 (es) Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma
Nouchi et al. Chronic left atrial volume overload abbreviates the action potential duration of the canine pulmonary vein myocardium via activation of IK channel
Nowakowska et al. The influence of retraction agents on cytoskeleton reorganization and oxidative stress in primary human gingival fibroblasts (HGFs)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/19 (2006.01), A61K 9/00 (2006.01), A61K 31

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2685 DE 21-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.